Total Funding
16
Total FundingSeries C raised
Growth Score
pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
458085
Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation.
Jay W. Schmelter: DirectorPast Role: Medtronic, marketing executive
C. R. Bard
About the Company
Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. Paclitaxel is an anti-proliferative drug commonly used to prevent arterial restenosis.
Lutonix DCB is very similar to a standard angioplasty balloon, but contains a special coating consisting of paclitaxel and a
proprietary carrier that facilitates the drug’s transfer to the arterial wall upon inflation. This highly efficient formulation allows Lutonix DCB to deliver a therapeutic dose to the artery wall, while keeping the dose of paclitaxel on the balloon as low as possible. A lower balloon drug load minimizes systemic drug exposure and is designed to maximize safety.
